Research on the Effectiveness of Neurorehabilitation After Stroke

Inclusion Criteria: * Signed written informed consent. * Age 18 to 80 years at the time of stroke onset. * Early rehabilitation period (up to 6 months post-stroke). * Diagnosis of acute cerebrovascular accident confirmed by MRI or CT. * Upper limb paresis severity between 0 and 3 on the 6-point Medical Research Council (MRC) muscle strength scale. * Ability and willingness to comply with the study protocol. * Demonstrated motivation for rehabilitation. Exclusion Criteria: * Montreal Cognitive Assessment scale (MoCA) score less than 10 points. * Hamilton Depression Rating Scale (Ham-D) score greater than 18 points. * Modified Rankin Scale (mRS) score greater than 4 points. * Pre-existing conditions that cause decreased muscle strength or increased muscle tone in the upper limbs (e.g., cerebral palsy, traumatic brain injury) or rigidity (e.g., Parkinson's disease, contractures). * Advanced arthritis or significant limitation of upper limb range of motion. * Absence of part of the upper limb due to amputation for any reason. * Any medical condition that may affect the conduct of the study or patient safety (e.g., mental illness). * Alcohol abuse or recreational drug use within the 12 months preceding the study. * Use of experimental medications or medical devices within the 30 days preceding the study. * Inability to comply with research procedures, as determined by the researcher. * The severity of the patient's condition, based on neurological or physical status, does not permit full rehabilitation. * Visual acuity less than 0.2 in the weakest eye according to the Sivtsev visual acuity chart. * Unstable angina and/or heart attack within the 30 days preceding the study. * Recurrent stroke. * Uncontrolled arterial hypertension. * Ataxia. * Presence of a pacemaker and/or other implanted electronic devices. * Use of muscle relaxants. * Peripheral neuropathy. * Coexisting diseases in an exacerbation or decompensated stage requiring active treatment. * Allergic reactions or other skin lesions at the EEG electrode application sites at the time of the study. * Acute urinary tract infections. * Acute thrombophlebitis. * Any form of epilepsy. * Benign and malignant neoplasms.